

TRIACORT

Corticosteroids

Recommended treatment of:

Systemic corticosteroid therapy of morbid conditions such as allergic syndromes, dermatosis, general rheumatoid arthritis, and other affections of the connective tissues.

For further detailed description, see back side.

Route of administration:

i.m.; intra-articular; intrabursal

Active principle:

Triamcinolone Acetonide

Dosage & pack size:

40 mg/1ml - Box of 3 vials

80 mg/2ml - Box of 3 vials

Registered for use in:

Italy, Macedonia, Lebanon



Recommended treatment of:

Systemic corticosteroid therapy of morbid conditions such as allergic syndromes (control of severe or incapacitating allergic conditions when conventional treatment is not feasible), dermatosis, general rheumatoid arthritis, and other affections of the connective tissues. The i.m. route is particularly useful when oral corticosteroid therapy is not feasible.

Triacort is also given by intra-articular or intra-bursal route or directly in the tendon sheaths and cystic tendon formations. These routes of administration allow to perform a valid short-

term local treatment of pain, swelling, and articular rigidity due to traumatic or rheumatoid arthritis, osteoarthritis, synovitis, bursitis and tenositis.

In the treatment of the general arthritis diseases, Triacort given by intra-articular injection is intended to support other conventional therapeutic measures. Limited morbid processes such as traumatic arthritis or bursitis represent typical indications for instituting intra-articular therapy.

